Market Closed -
Other stock markets
|
Pre-market 06:32:01 | |||
65.95 EUR | +0.69% | 66.1 | +0.23% |
06-19 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | |
06-18 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades |
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company benefits from high valuations in earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.90% | 6.33B | - | ||
+4.98% | 213B | B | ||
+7.44% | 184B | B- | ||
+28.22% | 153B | B- | ||
+33.19% | 113B | A- | ||
+1.22% | 63.66B | A- | ||
+16.51% | 53.53B | B+ | ||
+1.45% | 49.11B | B+ | ||
-4.53% | 38.73B | A | ||
+2.74% | 36.26B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AFX Stock
- AFX Stock
- Ratings Carl Zeiss Meditec AG